BioChaperone® Combo (Insulin Glargine / Lixisenatide)
Type 2 Diabetes
Phase 2Active
Key Facts
About Adocia
Adocia is a clinical-stage biotechnology company focused on developing innovative formulations and delivery systems for metabolic diseases, primarily diabetes and obesity. The company's strategy is built on four proprietary technology platforms (BioChaperone®, AdoShell®, AdOral®, AdoXLong) designed to enhance the efficacy and delivery of peptides, proteins, and cell therapies. Key achievements include advancing a Phase 3 ultra-rapid insulin and securing partnerships with major pharmaceutical firms like Eli Lilly and Tonghua Dongbao. Adocia's business model involves licensing out its validated assets post-proof-of-concept to global partners for development and commercialization.
View full company profileOther Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Diabetes Management Gel | Gelteq Limited | Formulation Development |
| Tolimidone | Biodexa Pharmaceuticals | Phase 2 |
| Generic Semaglutide Injection (Obeda) | Dr. Reddy's Laboratories | Approved |
| BioChaperone® Lispro | Adocia | Phase 3 |
| AJN003 (LuCI™) | AltrixBio | Pre-clinical |
| Hepatic Denervation for Type 2 Diabetes | Metavention | Feasibility |
| MVD-1 (SANA) | Eolo Pharma | Discovery |
| V-Go | MannKind | Approved |
| Type 2 Diabetes Management | iWel | Development |
| Band-assisted Duodenal Mucosal Resurfacing (DMR) | Endolastic | Pre-clinical |
| REMD-477 (Volagidemab) | REMD Biotherapeutics | Phase 2 (completed) |
| Undisclosed (Targeting IAPP) | Pangolin Therapeutics | Pre-clinical |